Biotech Acquisition Company Entered into a Merger Agreement with Blade Therapeutics
Shots:
- BAC signs a merger agreement with Blade for an enterprise value of ~$352.8M based on 58M in shares of common stock. Blade Therapeutics will rename as Blade Biotherapeutics & listed on Nasdaq under the ticker symbol "BBTX
- The transaction is expected to close in Q1'22 & will provide a pro forma cash balance of ~$254.3M to the combined company including ~$24.3M PIPE at $10.00/ share along with $230M of net cash in BAC's trust
- Blade plans to start a P-II study of cudetaxestat for IPF & a P-I clinical study of BLD-2184 for ND in H1'22. In P-I studies, cudetaxestat was well tolerated with a demonstrated PK/PD correlation and biomarker activity with a supportive clinical safety profile
Ref: PR Newswire | Image: Blade Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com